Feasibility and toxicity of high-dose therapy (HDT) supported by peripheral blood stem cells in elderly patients with multiple myeloma and non-Hodgkin's lymphoma: Survey from a single institution

American Journal of Hematology

Volumn 73, Issue 4, 2003, Pages 267-272

  Magagnoli, Massimo ^a   Castagna, Luca ^a   Balzarotti, Monica ^a   Sarina, Barbara ^a   Timofeeva, Inna ^a   Bertuzzi, Alexia ^a   Compasso, Silvana ^a   Nozza, Andrea ^a   Siracusano, Licia ^a   Santoro, Armando ^a  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

Author keywords

Elderly patients; Multiple myeloma; Non Hodgkin's lymphoma; PBSC transplantation

Indexed keywords

CARMUSTINE; CD34 ANTIGEN; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; MELPHALAN; NAVELBINE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER REGRESSION; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; DIARRHEA; DRUG MEGADOSE; DRUG RESPONSE; FEMALE; GASTROINTESTINAL TOXICITY; GERIATRIC PATIENT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HOSPITALIZATION; HUMAN; LIVER TOXICITY; MALE; MUCOSA INFLAMMATION; MULTIPLE MYELOMA; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; NONHODGKIN LYMPHOMA; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; STEM CELL MOBILIZATION; THROMBOCYTOPENIA;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DATA COLLECTION; FEASIBILITY STUDIES; FEMALE; GRAFT SURVIVAL; HUMANS; LEUKAPHERESIS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0041308064     PISSN: 03618609     EISSN: None     Source Type: Journal    
DOI: 10.1002/ajh.10384     Document Type: Article

References (28)

1. Bjorkstrand B, Goldstone AH, Ljungman P, Brandt L, Brunet S, Carlson K, et al. Prognostic factors in autologous stem cell transplantation for multiple myeloma: an EBMT Registry study: European Group for Bone Marrow Transplantation. Leuk Lymphoma 1994;15:265-272.
2. Cahn JY, Labopin M, Mandelli F, Goldstone AH, Eberhardt K, Reiffers J, et al. Autologous bone marrow transplantation for first remission acute myeloblastic leukemia in patients older than 50 years: a retrospective analysis of the European bone marrow transplant group. Blood 1995;85:575-579.
3. Kusnierz-Glaz CR, Schlegel PG, Wong RM, Schriber JR, Chao NJ, Amylon MD, et al. Influence of age on the outcome of 500 autologous bone marrow transplant procedures for hematologic malignancies. J Clin Oncol 1997;15:18-25.
4. Miller CB, Piantadosi S, Vogelsang GB, Marcellus DC, Grochow L, Kennedy MJ, et al. Impact of age on outcome of patients with cancer undergoing autologous bone marrow transplantation. J Clin Oncol 1996;14:1327-1332.
5. Sheridan WP, Begley CG, Juttner CA, Szer J, To LB, Maher D, et al. Effect of peripheral blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy. Lancet 1992;339:640-644.
6. Nemunaitis J, Rabinowe SN, Singer JW, Bierman PJ, Vose JM, Freedman AS, et al. Recombinant human granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer. N Engl J Med 1991;324:1773-1778.
7. Schmitz N, Linch DC, Dreger P, Goldstone AH, Boogaerts MA, Ferrant A, et al. Randomized trial of filgrastim mobilized peripheral blood progenitor cell transplantation versus autologous bone marrow transplantation in lymphoma patients. Lancet 1996;347:353-357.
8. Hughes WT, Armstrong D, Bodey GP, Brown AE, Edwards JE, Feld R, et al. Guidelines for the use of antimicrobial infectious agents in neutropenic patients with unexplained fever. Clin Infect Dis 1997;25:551-573.
9. Brundage MD, Pater JL, Zee B. Assessing the reliability of two toxicity scales: implications for interpreting toxicity data. J Natl Cancer Inst 1993;85:1138-1148.
10. Blade J, Samson D, Reece D, Apperley J, Bjorkstrand B, Gahrton G, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998;102:1115-1123.
11. Linch DC, Winfield D, Goldstone AH, Moir D, Hancock B, McMillan A, Chopra R, et al. Dose intensification with autologous bone marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNL1 randomised trial. Lancet 1993;341:1051-1054.
12. Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. New Engl J Med 1995;333:1540-1545.
13. Haioun C, Lepage E, Gisselbrecht C, Salles G, Coiffier B, Brice P, et al. Survival benefit of high dose therapy in poor risk aggressive non Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol. J Clin Oncol 2000;18:3025-3030.
14. Freedman AS, Takvorian T, Neuberg D, Mauch P, Rabinowe SN, Anderson KC, et al. Autologous bone marrow transplantation in poor-prognosis intermediate-grade and high-grade B-cell non Hodgkin's lymphoma in first remission: a pilot study. J Clin Oncol 1993;11:931-936.
15. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 1996;335:91-97.
16. Castagna L, Sarina B, Bertuzzi A, Nozza A, Magagnoli M, Balzarotti M, et al. High-dose chemotherapy followed by peripheral stem cell reinfusion in lymphoma patients: is post-reinfusion granulocyte-colony stimulating factor administration useful? Bone Marrow Transpl 2002;29(Suppl 2):134a.
17. Magagnoli M, Castagna L, Balzarotti M, Timofeeva I, Santoro A. High-dose chemotherapy supported by peripheral blood stem cell transplantation in elderly versus younger lymphoma patients: a matched analysis. Leuk Lymphoma (in press).
18. Badros A, Barlogie B, Siegel E, Morris C, Desikan R, Zangari M, et al. Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years. B J Haematol 2001;114:600-607.
19. Gorin NC, Labopin M, Pichard P, Sierra J, Fiere D, Rio B, et al. Feasibility and recent improvement of autologous stem cell transplantation for acute myelocytic leukemia in patients over 60 years of age: importance of the source of stem cell. Br J Haematol 2000;110:887-893.
20. Moreau P, Milpied N, Voillat L, Colombat P, Mahe B, Rapp MJ, Moreau A, et al. Peripheral blood stem cell transplantation as front-line therapy in patients aged 61 to 65 years: a pilot study. Bone Marrow Transpl 1998;21:1193-1196.
21. Stamatoullas A, Fruchart C, Khalfallah S, Buchonnet G, Contentin N, Bastit D, Tilly H. Peripheral blood stem cell transplantation for relapsed or refractory aggressive lymphoma in patients over 60 years of age. Bone Marrow Transpl 1997;19:31-35.
22. Sirohi B, Powles R, Treleaven J, Mainwaring P, Kulkarni S, Pandha H, et al. The role of autologous transplantation in patients with multiple myeloma aged 65 years and over. Bone Marrow Transpl 2000;25:533-539.
23. Olivieri A, Capelli D, Montanari M, Brunori M, Massidda D, Poloni A, et al. Very low toxicity and good quality of life in 48 elderly patients autotransplanted for hematological malignancies: a single center experience. Bone Marrow Transpl 2001;27:1189-1195.
24. Jantunen E, Mahlamaki E, Nousiainen T. Feasibility and toxicity of high-dose chemotherapy supported by peripheral blood stem cell transplantation in elderly patients (> 60 years) with non-Hodgkin's lymphoma: comparison with patients < 60 years treated within the same protocol. Bone Marrow Transpl 2000;26:737-741.
25. Sweetenham JW, Pearce R, Philip T, Proctor SJ, Mandelli F, Colombat P, et al. High-dose chemotherapy and autologous bone marrow transplantation for intermediate and high-grade non Hodgkin's lymphoma in patients aged 55 years and over: results from the European Group for Bone Marrow Transplantation. Bone Marrow Transpl 1994;14:981-987.
26. Leger CS, Bredeson C, Kearns B, Bence-Bruckler I, Atkins H, Huebsch L. Autologous blood and marrow transplantation in patients 60 years and older. Biol Blood Marrow Transpl 2000;6:204-210.
27. Fratino L, Serraino D, Repetto L. The Comprehensive Geriatric Assessment in elderly cancer patients. Preliminary results from the Italian Group of Geriatric Oncology-GIOGer. Rays 1999;24:53-60.
28. Monfardini S, Ferrucci L, Fratino L, del Lungo I, Serraino D, Zagonel V. Validation of a multidimensional evaluation scale for use in elderly cancer patients. Cancer 1996;77:395-402.